Three Rivers Pharmaceuticals is looking to flow powerful drugs into the vast sea of customer affordability. The drug maker develops, manufactures, and distributes specialty pharmaceutical products for the treatment of chronic conditions, particularly viral and fungal ailments. Three Rivers Pharmaceuticals makes and markets two hepatitis C treatments in the US market: Ribasphere (a generic version of the antiviral Ribavirin) and Infergen (a branded antiviral therapy). The company also sells an injectable antifungal medication, Amphotec (also known as Amphocil), in more than 40 countries.

IBEX Technologies Inc. company develops and sells a series of proprietary enzymes for use in pharmaceutical research, particularly for arthritis and oncology. It markets diagnostic assays for use in arthritis tests that monitor the deterioration of cartilage; other assays monitor the rebuilding of cartilage. IBEX also provides enzymes for use as reagents used in hemostasis monitoring devices (for blood coagulation detection during certain surgical procedures). The majority of the company's sales are in the US (50%), followed by Europe and Canada, where sales revenues are split evenly. The publicly-traded company, founded in 1972, is led by CEO Paul Baehr.

CSL Limited is a biopharmaceutical company engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates in three segments: CSL Behring, which is engaged in manufacturing, marketing and developing plasma products; Intellectual Property Licensing, which is engaged in licensing to unrelated third parties of intellectual property generated by the Company, and Other Human Health, which comprises CSL Bioplasma and CSL Biotherapies. These businesses manufacture and distribute biotherapeutic products. It operates in Australia, United States, Switzerland and Germany.

CyBio just might supplant the underpaid laboratory research assistant, so efficient are its automated systems; in all, the company makes it easier for laboratory scientists to focus on research and less on the repetitive processes involved therein. CyBio develops, produces, and markets technology platforms for drug discovery. With more than 15 years of experience in the field, CyBio provides the tools for pharmaceutical and agrochemical research, including pipetting instruments for liquid handling, incubating, and replicating, as well as software and system integration, for automated screening and reading.

Applied Genetic Technologies Corporation company was formed in 1999; funding partners include InterWest Partners, InterSouth Partners, and MedImmune Ventures. Applied Genetic Technologies Corporation (AGTC) applies itself to developing gene therapies for acquired and inherited genetic diseases. Its lead product is a treatment for Alpha One Antitrypsin Deficiency, which is an inherited cause of emphysema that is the most common hereditary disease in the Western World. Aside from causing lung disease in adults, it can also lead to liver disease in children. AGTC is also developing a treatment for Leber Congenital Amaurosis, which causes blindness, in collaboration with the universities of Florida and Pennsylvania, and Cornell University.

Grifols' focus is on producing plasma derivatives (plasma proteins for therapeutic use). This business generates about 70% of the group's annual revenue. Its diagnostic division manufactures devices, instrumentation, and reagents for clinical analysis labs, and markets products and equipment for blood banks. The third line of business, the hospital division, develops pharmaceutical products and medical devices used in hospital pharmacies. Clients include health care professionals and patients in more than 90 countries. Nearly three-quarters of Grifols' total sales come from international markets.

CombiMatrix Corporation company was founded in 1995 and is based in Mukilteo, Washington. CombiMatrix Corporation, together with its subsidiaries, develops technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology.CombiMatrix Corporation's products and services include CustomArray platform, an oligonucleotide array for genetic studies; CatalogArray Microarrays for gene expression studies, mutation analysis, and other studies; Micro-RNA Arrays that are used to study micro-RNA molecules; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. CombiMatrix Corporation also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, the company develops capabilities of producing arrays that utilize bacterial artificial chromosomes that enable genetic analysis; and a series of compounds to address various oncology-related diseases. It sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia.

Opko Health Inc. is a specialty healthcare company. The Company is focused on the discovery, development and commercialization of pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis and management of ophthalmic diseases and conditions. Its business consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. It focuses on exploring opportunities to acquire complementary pharmaceuticals, compounds, and technologies, which could, individually or in the aggregate, materially increase the scale of the Company’s business. On May 6, 2008, the Company completed the acquisition of Vidus Ocular, Inc. (Vidus).

GSK Consumer Healthcare, a unit of druggernaut GlaxoSmithKline, makes and sells a wide range of over-the-counter drugs, oral care products, and nutritionals. Brands and products range from oral care (Aquafresh toothpaste) to dermatology (Zovirax cold sore medication), with all kinds of analgesics (Panadol), gastrointestinal remedies (Tums), and smoking-cessation products (Nicoderm) in between. GSK Consumer Healthcare also makes a variety of vitamins and natural remedies, as well as the weight loss product alli.

LGC (Holdings) Limited company provides chemical, DNA and other scientific analysis through four operating divisions: LGC forensics, life and food sciences, research and technology, and LGC standards. Its customers are involved in such areas as drug development, health care services, chemicals and petrochemicals, law enforcement, and environmental quality and maintenance. The company's LGC Prochem unit sells enzymes, proteins, reagents, and other laboratory supplies. Investment firm 3i Group owns about 30% of LGC, as does its employees.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.